
    
      Study D9108C00001 (COAST) is a Phase 2, open-label, multicenter, randomized multidrug
      platform study assessing the efficacy and safety of durvalumab alone vs durvalumab in
      combination with novel agents in subjects with locally advanced, unresectable, Stage III
      non-small cell lung cancer (NSCLC).
    
  